

Mechanisms and Predictors of Acute Kidney Injury with Perioperative Rosuvastatin in Patients Undergoing Cardiac Surgery

RS Wijesurendra^{1,2}, R Sardell², R Jayaram¹, N Samuel², Z Chen², N Staplin^{2,3}, R Collins², Z Zheng⁴, R Haynes^{2,3}, M Hill^{2,3}, J Emberson^{2,3}, B Casadei¹

¹Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

²Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

³Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

⁴Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Short title: Rosuvastatin and Postoperative Acute Kidney Injury

Corresponding Author: Barbara Casadei MD DPhil FRCP FMedSci FESC

Address: Division of Cardiovascular Medicine, University of Oxford
Level 6, West Wing, John Radcliffe Hospital, Headley Way
Oxford, UK, OX3 9DU

Telephone: +44 1865 234664

Email: barbara.casadei@cardiov.ox.ac.uk

Abstract word count: 349

Main text word count: 3664

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract**

2 **Background**

3 In patients undergoing cardiac surgery perioperative statin therapy has been associated with
4 an unexpected increase in postoperative plasma creatinine. Here we investigated
5 mechanisms and predictors of acute kidney injury (AKI) in 1922 patients enrolled in the Statin
6 Therapy in Cardiac Surgery (STICS) randomized placebo-controlled trial of perioperative
7 rosuvastatin (20 mg once daily).

8 **Methods**

9 AKI was defined according to international guidelines (KDIGO) using plasma creatinine, and
10 also by cystatin C. Potentially mechanistically relevant plasma/serum biomarkers of muscle
11 injury, inflammation, and kidney injury were investigated, including total creatine kinase (CK),
12 growth differentiation factor 15 (GDF-15), interleukin-6 (IL-6), procalcitonin (PCT), placental
13 growth factor (PLGF), kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated
14 lipocalin (NGAL).

15 **Results**

16 At 48 hours post-surgery, the incidence of AKI was greater in the rosuvastatin group than in
17 the placebo group when defined by a rise in creatinine (24.7% vs 19.3%, $p=0.005$) or cystatin
18 C (9.2% vs 5.1%, $p<0.001$); the majority of AKI was stage 1 in severity (87% when defined by
19 creatinine, and 80% when defined by cystatin C). Compared with placebo, rosuvastatin led to
20 higher postoperative serum levels of KIM-1 (278 ± 5 pg/ml versus 259 ± 5 pg/ml, $P=0.01$), and
21 to more frequent elevations in CK to $>10x$ and $>40x$ the baseline level (30.9% versus 26.5%,
22 $p=0.032$, and 2.1% versus 0.7%, $p=0.016$, respectively), whereas postoperative
23 concentrations of GDF-15, IL-6, PCT, PLGF, and NGAL were similar between groups. In
24 multivariable analyses, insulin treatment, baseline KIM-1, combined coronary artery bypass
25 grafting (CABG) and aortic valve replacement (AVR) surgery, and allocation to rosuvastatin
26 were all independently associated with AKI as defined by creatinine or cystatin C. Odds ratios
27 for rosuvastatin compared to placebo for both creatinine- and cystatin C-defined AKI were
28 not materially altered by further adjustment for post-randomization increases in CK.

1 **Conclusions**

2 Perioperative rosuvastatin initiation increased the absolute risk of AKI after cardiac surgery
3 by 4-5%, whether defined by creatinine or cystatin C, and led to higher post-operative KIM-1,
4 suggesting a deleterious effect on renal function, possibly mediated by proximal tubular
5 injury. Insulin treatment, baseline KIM-1, combined CABG/AVR surgery, and allocation to
6 rosuvastatin were all independently associated with AKI by any definition.

1 Introduction

2 Statins are one of the most widely used classes of prescription medicine across the world^{1, 2}.
3 The efficacy and safety of statins have been robustly demonstrated³, with relative reductions
4 in rates of major cardiovascular events proportional to the absolute LDL cholesterol
5 reduction⁴. In addition to reducing synthesis of cholesterol by competitive inhibition of HMG-
6 CoA reductase, various pleiotropic effects of statins, including anti-inflammatory⁵ and
7 antioxidant^{6, 7} effects, have also been described. As a result, statins have been proposed as a
8 potential modulator of clinical outcomes after surgery⁸. In particular, some observational
9 studies suggested that statins may be associated with a reduced risk of acute kidney injury
10 (AKI) after cardiac surgery⁹, although this has not been a consistent finding^{10, 11}. Any effect on
11 postoperative AKI is relevant as this complication affects as many as 25-30% of patients after
12 cardiac surgery^{12, 13} and is associated with longer hospital stay and increased risk of
13 mortality¹⁴⁻¹⁶.

14 The Statin Therapy In Cardiac Surgery (STICS) trial was a randomized double-blind placebo-
15 controlled trial that aimed to provide definitive evidence regarding the effects of
16 perioperative statin therapy on the co-primary outcomes of postoperative atrial fibrillation
17 and perioperative cardiac injury in patients undergoing elective cardiac surgery¹⁷. Whilst
18 perioperative rosuvastatin 20 mg once daily did not significantly affect either co-primary
19 outcome, AKI defined by Acute Kidney Injury Network criteria¹⁸ (a pre-specified secondary
20 outcome) was unexpectedly found to be significantly more common in rosuvastatin allocated
21 patients¹⁷.

22 In addition to STICS, a smaller trial of high-dose perioperative atorvastatin in patients
23 undergoing cardiac surgery did not support the initiation of statin therapy to prevent
24 postoperative AKI after showing a null result and being stopped prematurely after 615
25 patients had been randomized¹⁹. Other studies investigating the incidence of AKI in patients
26 treated with statins compared to control therapy after cardiac surgery have reported variable
27 results, but these were all small (≤ 200 patients each) and many had additional limitations²⁰⁻
28 ²⁸.

29 To understand the mechanism and predictors of post-operative AKI in patients undergoing
30 cardiac surgery treated with perioperative rosuvastatin, we undertook further analysis of the

1 STICS data and samples, including measurement of cystatin C as well as analysis of several
2 biomarkers relevant to muscle injury, inflammation, and kidney injury.

3

4 **Methods**

5 *Trial design*

6 The methodology and primary results of the STICS trial (NCT01573143) have been published
7 previously¹⁷. Briefly, STICS was a randomized double-blind placebo-controlled trial of
8 perioperative rosuvastatin in 1922 Chinese patients undergoing elective cardiac surgery. Men
9 and women who were 18 years of age or older and were scheduled to undergo elective
10 coronary-artery bypass grafting (CABG), surgical aortic-valve replacement (AVR), or both were
11 eligible if they were in sinus rhythm and were not taking antiarrhythmic medication (other
12 than beta-blockers). Patients were excluded if they had moderate or severe mitral-valve
13 disease, a creatinine level, >2.3 mg per deciliter [200 μ mol per liter] or contraindications to
14 statin therapy. All the participants provided written informed consent before enrollment. The
15 trial protocol was approved by the ethics committees at Fuwai Hospital in Beijing (where
16 patients were recruited) and at the University of Oxford in the United Kingdom (where all
17 electrocardiographic, blood, and statistical analyses were performed).

18 Eligible patients underwent transthoracic echocardiography for evaluation of left ventricular
19 ejection fraction and left atrial size. Any prescribed statin therapy was stopped, and patients
20 were then randomly assigned to receive rosuvastatin at a dose of 20 mg once daily or
21 matching placebo tablets for up to 8 days before surgery and for 5 days thereafter. Blood
22 samples were obtained at randomization and at 6, 24, 48, and 120 hours after surgery.

23

24 *Biomarker analysis*

25 Cystatin C (an alternative biomarker to creatinine for diagnosis of AKI, with some advantages
26 in the estimation of GFR²⁹ particularly in the context of an acute physiological insult³⁰), growth
27 differentiation factor 15 (GDF-15; a member of the TGF- β cytokine superfamily that may be
28 induced in response to tissue injury and is associated with chronic kidney disease
29 progression³¹), interleukin-6 (IL-6; a pleiotropic cytokine with local and systemic expression

1 that is linked to renal ischemia and AKI³²), procalcitonin (PCT; a marker of systemic
2 inflammatory response³³), placental growth factor (PLGF; a proatherogenic cytokine which is
3 present at higher concentrations in individuals with kidney disease³⁴), kidney injury molecule-
4 1 (KIM-1; a blood biomarker that specifically reflects renal proximal tubular injury³⁵ and is
5 associated with progression to renal failure³⁶), and neutrophil gelatinase-associated lipocalin
6 (NGAL; a biomarker of renal epithelial injury³⁷) were measured in 960 patients allocated to
7 rosuvastatin and 962 patients allocated to placebo at baseline and after surgery. Other
8 biochemical markers investigated included total creatine kinase (CK; which is linked to an
9 increased risk of AKI in the context of rhabdomyolysis³⁸), N-terminal pro-BNP (NT-proBNP),
10 creatinine, LDL cholesterol, and Troponin I. Follow-up values were at 48 hours for CK, cystatin
11 C, KIM-1, and NGAL, and at 6 hours for GDF-15, IL-6, PLGF and PCT.

12 All blood assays were carried out by the CTSU's Wolfson Laboratories, University of Oxford,
13 blind to the study treatment allocation. Serum and plasma were separated by centrifugation
14 at 1300g for 10 minutes at room temperature. Further details of the assays used and their
15 respective uncertainties are contained in the **Supplementary Methods**.

16

17 *Definition of acute kidney injury (AKI)*

18 AKI by serum creatinine was defined based on KDIGO criteria³⁹. Creatinine-defined AKI at 48
19 hours was defined as an increase from baseline in the creatinine level of ≥ 0.3 mg per deciliter
20 (≥ 26.5 μmol per liter) or an increase by a factor of at least 1.5. Creatinine-defined AKI severity
21 was sub-divided based on increase from baseline creatinine by a factor of less than 2 (stage
22 1); increase from baseline creatinine by a factor of 2 to 3 (stage 2); or increase from baseline
23 creatinine by a factor of more than 3, a rise to a creatinine level of ≥ 4.0 mg per deciliter (≥ 350
24 μmol per liter), or the initiation of renal-replacement therapy (stage 3).

25 AKI was also separately defined using serum cystatin C⁴⁰. In this case, AKI at 48 hours was
26 defined as an increase from baseline in the cystatin C level by a factor of at least 1.5. Cystatin
27 C-defined AKI severity was sub-divided based on increase from baseline cystatin C by a factor
28 of less than 2 (stage 1); increase from baseline cystatin C by a factor of 2 to 3 (stage 2); or
29 increase from baseline cystatin C by a factor of more than 3, or the initiation of renal-
30 replacement therapy (stage 3). A sensitivity analysis with an alternative definition of stage 1

1 AKI, to include an increase from baseline in the Cystatin C level by a factor of at least 1.1 to
2 less than 2, was also undertaken.

3

4 *Statistical analysis*

5 All randomized comparisons were performed according to the intention-to-treat principle.
6 We used odds ratios and 95% confidence intervals for between-group comparisons of post-
7 operative AKI. ANCOVA was used to compare biomarkers after surgery, with adjustment for
8 baseline values. Analyses were performed on the log scale for all biomarkers and then
9 transformed back to the original scale as geometric means. For dichotomous outcomes,
10 patients with missing data were assumed not to have had the outcome. Missing values for
11 biomarkers were estimated by means of multiple imputation, with 10 replicate sets and
12 combination across sets with the use of Rubin's methods⁴¹.

13 Comparisons of post-operative AKI, creatinine, and cystatin C between treatment groups
14 were performed in subgroups defined according to age at baseline (≤ 60 years vs > 60 years),
15 sex, previous statin use (yes vs no), troponin I concentration (≤ 0.04 ng per milliliter vs > 0.04
16 ng per milliliter), duration of preoperative randomly assigned regimen (≤ 2 days vs > 2 days),
17 type of surgery (on-pump vs off-pump; CABG vs. aortic-valve replacement), postoperative use
18 of nonsteroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids (yes vs no), and AKI risk
19 in those who received CABG and/or AVR (low/medium/high). Observed effects in different
20 subgroups were compared with the use of chi-square tests for heterogeneity or trend.

21 To identify factors associated with post-operative AKI risk, analyses were restricted to 1,852
22 patients who underwent CABG or AVR surgery (or both). Patients with missing creatinine or
23 cystatin C at baseline and/or 48 hours were assumed not to have had the outcome (see
24 **Supplementary Table 1** for numbers of participants with missing values). For dichotomous
25 variables (medical history and medication use) missing values were replaced with the mode.
26 Missing biomarkers were replaced with the mean/median. Separate age-adjusted logistic
27 regression models were used to identify which baseline variables were associated with odds
28 of AKI. Stepwise multivariable forwards and backwards selection models including only those
29 variables found to be significantly associated with odds of AKI at the 5% level in age-adjusted
30 models were then used to develop the final prediction model (selecting the model with the

1 lowest Bayesian Information Criterion). Age was retained in the multivariable model
2 irrespective of its statistical significance. Model discrimination for the final prediction model
3 was assessed using the C statistic. Using the final prediction model, 3 risk groups (low,
4 medium and high) were defined using tertiles of predicted risk.

5 Cross tabulations of the extent of increase in CK at 48 hours with AKI stage were used to assess
6 the association between CK elevations and post-operative AKI. The final model was
7 additionally adjusted for increases in CK to estimate the relevance of treatment allocation to
8 odds of AKI independent of CK elevations.

9

10 **Results**

11 Baseline characteristics of the 1922 patients who underwent randomization are shown in
12 **Table 1**. After randomization, surgery was cancelled for 48 patients (28 patients in the
13 rosuvastatin group and 20 in the placebo group). Of those who received surgery, 1614 (86%)
14 underwent CABG (including 53 [3%] who, in addition, had AVR), 185 (10%) underwent AVR
15 alone, and a further 75 (4%) underwent some other type of surgery; 55% of the operations
16 were on-pump. Overall 66% of patients were statin-naïve (639/960 in the rosuvastatin group
17 and 630/962 in the placebo group). The prevalence of self-reported chronic kidney disease
18 (CKD) was $\leq 1\%$ in both groups (10/960 in the rosuvastatin group and 8/962 in the placebo
19 group). The number of participants in whom each biomarker result was missing at baseline
20 and follow-up in each group are reported in **Supplementary Table 1**; overall, >91% of results
21 were available.

22

23 *Post-operative renal function and incidence of AKI*

24 The incidence of creatinine-defined AKI was greater in the rosuvastatin group than in the
25 placebo group (24.7% vs 19.3%, odds ratio [OR] 1.37, 95% confidence interval [CI] 1.10-1.70,
26 $p=0.005$; **Figure 1A**), as was the incidence of cystatin C defined AKI (9.2% vs 5.1%, OR 1.86,
27 95% CI 1.29-2.67, $p<0.001$; **Figure 1B**). In a sensitivity analysis in which the cystatin C definition
28 of AKI was expanded to include an increase from baseline in the cystatin C level by a factor of
29 at least 1.1, the incidence of AKI was 46.0% vs 36.7% (OR 1.47, 95% CI 1.23-1.77, $p<0.001$).

1 Creatinine and cystatin C levels in both treatment groups increased from baseline to 48 hours
2 after surgery; however, baseline-adjusted creatinine and cystatin C levels at 48 hours were
3 significantly higher in rosuvastatin-allocated than placebo-allocated patients (1.02 ± 0.01
4 mg/dL vs 0.99 ± 0.01 mg/dL , $p=0.007$, **Figure 1C**; and 1.07 ± 0.01 mg/L vs 1.02 ± 0.01 mg/L ,
5 $p<0.001$, **Figure 1D**; respectively).

6 The breakdown of absolute excess in creatinine-defined AKI in the rosuvastatin group
7 compared with the placebo group was: stage 1 ($3.5\pm 1.8\%$); stage 2 ($1.3\pm 0.6\%$); and stage 3
8 ($0.5\pm 0.5\%$). When assessed by cystatin C, the corresponding excess values were: stage 1
9 ($2.5\pm 1.1\%$); stage 2 ($1.3\pm 0.4\%$); and stage 3 ($0.3\pm 0.4\%$). The proportional effect of allocation
10 to rosuvastatin on post-operative creatinine-defined or cystatin C defined AKI was similar in
11 different types of patients (**Figure 2** and **Supplementary Figure 1**), including in those who
12 were already receiving statins compared to those who were statin-naïve. The effect of
13 allocation to rosuvastatin on mean levels of creatinine and cystatin-C at 48 hours after surgery
14 was also similar in different types of patient (**Supplementary Figure 2** and **Supplementary**
15 **Figure 3**).

16

17 *Serum biomarkers relevant to post-operative AKI by statin allocation*

18 Concentrations of GDF-15, IL-6, PCT, PLGF, KIM-1 and NGAL were all substantially higher after
19 surgery than at baseline (**Figure 3**). For GDF-15, IL-6, PCT, PLGF and NGAL there was no
20 significant difference in this rise between rosuvastatin-allocated and placebo-allocated
21 patients, but for KIM-1 the rise was significantly higher for patients allocated rosuvastatin
22 (baseline-adjusted mean KIM-1 concentration at 48 hours: 278 ± 5 pg/ml versus 259 ± 5 pg/ml
23 respectively, $p=0.01$; **Figure 3E**).

24 The incidence of elevation in CK at 48 hours after surgery to $>5x$ the baseline level was similar
25 in both groups (37.1% in the rosuvastatin group vs 37.5% in the placebo group, $p=0.84$).
26 However, elevations to $>10x$ and $>40x$ the baseline level were more common in the
27 rosuvastatin group (30.9% versus 26.5%, $p=0.032$, and 2.1% versus 0.7%, $p=0.016$,
28 respectively). The extent of increase in CK at 48 hours after surgery was correlated with the
29 likelihood of AKI, both for creatinine-defined AKI (**Supplementary Table 2**) and cystatin C-
30 defined AKI (**Supplementary Table 3**).

1

2 *Predictors of post-operative AKI*

3 The individual and joint relevance of clinical factors and baseline biomarkers to the odds of
4 post-operative creatinine and cystatin C-defined AKI were investigated (**Table 2** and **Table 3**,
5 respectively).

6 In the fully-adjusted multivariable analysis, age, insulin treatment, lack of recent exposure to
7 contrast agent, log baseline creatinine, log baseline KIM-1, combined CABG and AVR surgery,
8 and allocation to rosuvastatin were all independently associated with significantly higher
9 odds of creatinine-defined AKI. The overall C-statistic corresponding to this final model was
10 0.66 (95% CI 0.63-0.69). In this fully-adjusted model, the conditional odds ratio associated
11 with allocation to rosuvastatin was 1.43 (95% CI 1.14 – 1.80). This was not materially altered
12 by further adjustment for increases in CK (OR with adjustment for CK increase 1.34 [95% CI
13 1.07-1.69]).

14 When considering cystatin C-defined AKI, insulin treatment, ACE or ARB treatment, log
15 baseline KIM-1, log baseline NT-pro BNP, combined CABG and AVR surgery, and allocation to
16 rosuvastatin were all independently associated with significantly higher odds of AKI. The
17 overall C-statistic corresponding to this final model was 0.73 (95% CI 0.68-0.78). In this fully-
18 adjusted model, the conditional odds ratio associated with allocation to rosuvastatin was 2.01
19 (95% CI 1.38 – 2.93). This was not materially altered by further adjustment for increases in CK
20 (OR with adjustment for CK increase 1.92 [95% CI 1.31-2.81]).

21 Overall, insulin treatment, baseline KIM-1, combined CABG and AVR surgery, and allocation
22 to rosuvastatin were all independently associated with AKI by any definition (**Table 4**).

23 When risk factors were combined to create risk scores for AKI and participants were divided
24 into tertiles of predicted risk based on these scores, the effect of allocation to rosuvastatin
25 compared to placebo was similar across risk groups (p for trend = 0.26 for creatinine-defined
26 AKI, **Figure 2**; p for trend = 0.13 for cystatin C-defined AKI, **Supplementary Figure 1**).

1

2 **Discussion**

3 This study demonstrated that allocation to rosuvastatin compared with placebo increased the
4 absolute risk of post-operative AKI by 4-5% in patients undergoing cardiac surgery, and led to
5 higher post-operative KIM-1, suggesting a deleterious effect of rosuvastatin on renal function
6 possibly mediated by proximal tubular injury³⁶. In multivariable analyses, insulin treatment,
7 baseline KIM-1, combined CABG and AVR surgery, and allocation to rosuvastatin were all
8 independently associated with AKI by any definition. Although rosuvastatin also led to a
9 significant increase in post-operative CK, adjustment for this did not materially change the
10 estimated effect of allocation to rosuvastatin on post-operative AKI. Overall, the adverse
11 effect of perioperative rosuvastatin on renal function is particularly relevant given its lack of
12 efficacy in terms of reducing postoperative AF or perioperative myocardial injury¹⁷.

13 The mechanism of AKI in the postoperative patient is usually multi-factorial, and often related
14 to renal ischaemia, nephrotoxic medications, hypovolaemia, and sepsis⁴². Cardiac surgery and
15 major vascular surgery are particularly associated with risk of AKI, probably due to frequent
16 combination of underlying chronic kidney disease (possibly vascular in origin) and the degree
17 of insult resulting from the surgery. In line with this paradigm, previously identified risk factors
18 for development of AKI include age, congestive heart failure, prior myocardial
19 revascularisation, type 1 diabetes mellitus or pre-operative hyperglycaemia, and elevated
20 pre-operative serum creatinine⁴³. Interventions to reduce risk of postoperative AKI are limited
21 and largely conservative, based around avoidance of nephrotoxic medications,
22 hyperglycaemia, and hypo- or hypervolaemia.

23 In the present study, we measured a variety of additional novel biomarkers in order to further
24 investigate potential mechanisms of AKI in this patient group. In addition to creatinine, serum
25 cystatin C was also used to diagnose AKI, as the latter may be less affected by non-GFR-related
26 factors such as age, gender, muscle mass, and ethnicity²⁹. Baseline KIM-1 was independently
27 associated with the risk of post-operative AKI, in keeping with previous data suggesting that
28 KIM-1 is a biomarker of acute and chronic kidney injury^{35, 36}. The post-operative concentration
29 of KIM-1 was also higher in patients allocated to rosuvastatin compared to placebo,
30 suggesting that allocation to rosuvastatin may exacerbate renal proximal tubular injury³⁵ in

1 the context of cardiac surgery. These results are in contrast to those for NGAL, which is a
2 marker of renal epithelial tissue injury. Similarly, there were also no significant differences in
3 serum GDF-15, IL6, PCT, or PLGF between the groups, suggesting that the adverse effect of
4 perioperative rosuvastatin on renal function may be independent of systemic inflammation
5 and renal epithelial tissue injury.

6 These findings are contrary to prior interest in the use of statins to reduce post-operative
7 complications in patients undergoing high risk surgery based on the described pleiotropic
8 effects of statins, including anti-inflammatory⁵ and antioxidant^{6, 7} effects. Current ESC and
9 ACC/AHA practice guidelines on the cardiovascular evaluation and management of patients
10 undergoing non-cardiac surgery both recommend consideration of initiation of statin therapy
11 in the peri-operative period in individuals undergoing vascular surgery who are not already
12 receiving long-term statin therapy^{44, 45}.

13 Beyond the context of cardiac surgery, myotoxicity is recognized as a rare side-effect of statin
14 therapy⁴⁶. This is heterogeneous in presentation but can rarely result in rhabdomyolysis,
15 characterized by the leakage of muscle-cell contents (including CK and myoglobin) into the
16 circulation⁴⁷. An increase in serum myoglobin concentration is described after cardiac
17 surgery, and independently predicts the incidence of postoperative AKI⁴⁸. Although allocation
18 to rosuvastatin in STICS did significantly increase post-operative CK, adjustment for this
19 increase in CK did not significantly attenuate the effect of rosuvastatin on risk of
20 postoperative AKI, implying that a statin-associated muscle injury does not contribute to the
21 latter.

22 The finding that perioperative initiation of rosuvastatin 20mg increases the risk of AKI after
23 cardiac surgery is clinically relevant, particularly in the context of a null effect of statin therapy
24 on post-operative complications¹⁷. Although previous randomized controlled trials have
25 demonstrated a renal protective effect of statins on contrast-induced AKI⁴⁹, the present data
26 indicate that rosuvastatin has an adverse effect on renal function in patients undergoing
27 cardiac surgery, perhaps reflecting differences in the nature and physiological insult of the
28 procedure itself. A systematic review and meta-analysis of 11 trials of perioperative statin
29 therapy in cardiac surgery (including STICS) confirmed a higher incidence of AKI in cardiac
30 surgery patients receiving perioperative statins compared to control (RR = 1.15 [95% CI 1.00-
31 1.31], p=0.05), with no significant heterogeneity between trials⁵⁰. In addition to their small

1 size, many of the trials had other important limitations including a failure to include AKI as a
2 pre-specified outcome with a clear definition of the diagnostic criteria (7 trials), lack of
3 confirmation of an intention-to-treat analysis (6 trials), and lack of allocation concealment or
4 blinding (5 trials). However, when the meta-analysis was limited to the 5 trials (including
5 STICS) that were assessed as having a low risk of bias, a similar result was seen (RR = 1.17
6 [95% CI 1.02-1.34], $p=0.03$)⁵⁰. STICS contributed the strongest evidence on this topic by
7 including 1922 of 3384 (57%) patients and more importantly also accounting for 423 of 650
8 (65%) AKI events. Overall, the size and robustness of the STICS trial provided a unique
9 opportunity to further investigate the mechanisms and predictors of AKI in the present study.

10 It is important to emphasise that the majority of the excess in AKI following rosuvastatin use
11 in STICS was relatively minor (i.e. stage 1). Whilst incompletely resolved AKI could lead to CKD
12 and increase the risk of future cardiovascular events, it is likely that the prognostic benefit
13 from statin therapy in terms of long-term LDL reduction would outweigh any such risk. The
14 STICS trial does not directly address the question of whether existing statin therapy should be
15 temporarily suspended at the time of cardiac surgery, since only approximately one third of
16 patients were already prescribed statins, although there was no evidence of a differential
17 effect on AKI in this subgroup compared to the statin-naïve group. In the absence of further
18 trials, temporary statin cessation in the perioperative period in patients undergoing elective
19 cardiac surgery may be a reasonable option to consider on a case-by-case basis, particularly
20 in patients with several other risk factors for development of AKI. If such measures were
21 undertaken, close attention would need to be paid to statin reintroduction after the risk of
22 perioperative AKI has receded.

23 This study has a number of strengths including its large size, high levels of adherence to the
24 treatment regimen, robust and blinded evaluation of AKI (as a pre-specified outcome) using
25 both creatinine and serum cystatin C, and evaluation of a number of other biomarkers that
26 are potentially mechanistically linked to development of postoperative AKI. Limitations
27 include lack of urine samples to explore other biomarkers of renal tubular function, and a lack
28 of data regarding post-operative urine output, which could therefore not be incorporated
29 within the definitions of AKI used in the study. It is not possible to determine from this dataset
30 whether the findings reported are specific to the patients' ethnic group and/or to rosuvastatin

1 (versus other statins), and information is also not available on longer-term renal outcomes
2 after the perioperative period.

3 In summary, perioperative rosuvastatin initiation increased the absolute risk of AKI (however
4 defined) after cardiac surgery by 4-5%, and led to higher post-operative KIM-1, suggesting a
5 deleterious effect on renal function possibly mediated by proximal tubular injury. Insulin
6 treatment, baseline KIM-1, combined CABG and AVR surgery, and allocation to rosuvastatin
7 were all independently associated with AKI by any definition.

1 **Acknowledgements**

2 We thank the patients who agreed to take part in the trial; the cardiac surgery teams in the
3 Department of Cardiac Surgery, Fuwai Hospital, Beijing; the research support staff in the
4 China–Oxford Center for International Health Research, Fuwai Hospital; and the technicians
5 in the Wolfson Laboratories of the Clinical Trial Service Unit and Epidemiological Studies Unit,
6 Oxford, United Kingdom.

7

8 **Sources of Funding**

9 Supported by the British Heart Foundation, the European Network for Translational Research
10 in Atrial Fibrillation of the European Commission Seventh Framework Program, the NIHR
11 Oxford Biomedical Research Centre, the U.K. Medical Research Council, an unrestricted grant
12 from AstraZeneca, and in-kind by Roche Diagnostics (blood assays).

13

14 **Disclosures**

15 BC is receiving support in-kind from iRhythm (ECG monitors) for clinical studies on atrial
16 fibrillation.

17

1 References

- 2 1. O'Keeffe A, Nazareth I and Petersen I. Time trends in the prescription of statins for the primary
3 prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health
4 Improvement Network primary care data. *Clinical Epidemiology*. 2016.
- 5 2. Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, Virani SS, Blankstein R,
6 Khera A, Blaha MJ, Blumenthal RS, Lloyd-Jones D and Nasir K. National Trends in Statin Use and
7 Expenditures in the US Adult Population From 2002 to 2013. *JAMA Cardiology*. 2017;2.
- 8 3. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of
9 individual data from 174 000 participants in 27 randomised trials. *The Lancet*. 2015;385:1397-1405.
- 10 4. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from
11 170 000 participants in 26 randomised trials. *The Lancet*. 2010;376:1670-1681.
- 12 5. Pinho-Gomes AC, Reilly S, Brandes RP and Casadei B. Targeting Inflammation and Oxidative
13 Stress in Atrial Fibrillation: Role of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibition with
14 Statins. *Antioxidants & Redox Signaling*. 2014;20:1268-1285.
- 15 6. Jayaram R, Jones M, Reilly S, Crabtree MJ, Pal N, Goodfellow N, Nahar K, Simon J, Carnicer R,
16 DeSilva R, Ratnatunga C, Petrou M, Sayeed R, Roalfe A, Channon KM, Bashir Y, Betts T, Hill M and
17 Casadei B. Atrial nitroso-redox balance and refractoriness following on-pump cardiac surgery: a
18 randomized trial of atorvastatin. *Cardiovascular Research*. 2022;118:184-195.
- 19 7. Reilly SN, Jayaram R, Nahar K, Antoniadis C, Verheule S, Channon KM, Alp NJ, Schotten U and
20 Casadei B. Atrial Sources of Reactive Oxygen Species Vary With the Duration and Substrate of Atrial
21 Fibrillation. *Circulation*. 2011;124:1107-1117.
- 22 8. Le Manach Y, Coriat P, Collard Charles D, Riedel B and Riou B. Statin Therapy within the
23 Perioperative Period. *Anesthesiology*. 2008;108:1141-1146.
- 24 9. Layton JB, Kshirsagar AV, Simpson RJ, Pate V, Jonsson Funk M, Stürmer T and Brookhart MA.
25 Effect of Statin Use on Acute Kidney Injury Risk Following Coronary Artery Bypass Grafting. *The*
26 *American Journal of Cardiology*. 2013;111:823-828.
- 27 10. Argalious M, Xu M, Sun Z, Smedira N and Koch CG. Preoperative Statin Therapy Is Not
28 Associated with a Reduced Incidence of Postoperative Acute Kidney Injury After Cardiac Surgery.
29 *Anesthesia & Analgesia*. 2010;111:324-330.
- 30 11. Shvartz V, Khugaeva E, Kryukov Y, Sokolskaya M, Ispiryan A, Shvartz E, Petrosyan A, Dorokhina
31 E, Bockeria L and Bockeria O. Long-Term Preoperative Atorvastatin or Rosuvastatin Use in Adult
32 Patients before CABG Does Not Increase Incidence of Postoperative Acute Kidney Injury: A Propensity
33 Score-Matched Analysis. *Pathophysiology*. 2022;29:354-364.
- 34 12. Karkouti K, Wijeyesundera DN, Yau TM, Callum JL, Cheng DC, Crowther M, Dupuis J-Y, Fremes
35 SE, Kent B, Laflamme C, Lamy A, Legare J-F, Mazer CD, McCluskey SA, Rubens FD, Sawchuk C and
36 Beattie WS. Acute Kidney Injury After Cardiac Surgery. *Circulation*. 2009;119:495-502.
- 37 13. Rosner MH and Okusa MD. Acute Kidney Injury Associated with Cardiac Surgery. *Clinical*
38 *Journal of the American Society of Nephrology*. 2006;1:19-32.
- 39 14. Antunes P, Prieto D, Ferraodeoliveira J and Antunes M. Renal dysfunction after myocardial
40 revascularization. *European Journal of Cardio-Thoracic Surgery*. 2004;25:597-604.
- 41 15. Chertow GM, Lazarus JM, Christiansen CL, Cook EF, Hammermeister KE, Grover F and Daley J.
42 Preoperative Renal Risk Stratification. *Circulation*. 1997;95:878-884.
- 43 16. Chertow GM, Levy EM, Hammermeister KE, Grover F and Daley J. Independent Association
44 between Acute Renal Failure and Mortality following Cardiac Surgery 11Access the "Journal Club"
45 discussion of this paper at <http://www.elsevier.com/locate/ajmselect/22The> VA Continuous
46 Improvement in Cardiac Surgery Program was initially supported by the Health Services Research and
47 Development Service, Veterans Health Administration, and funded through VA Patient Care Services.
48 *The American Journal of Medicine*. 1998;104:343-348.
- 49 17. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins
50 R and Casadei B. Perioperative Rosuvastatin in Cardiac Surgery. *New England Journal of Medicine*.
51 2016;374:1744-1753.

- 1 18. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG and Levin A. Acute Kidney
2 Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Critical Care*.
3 2007;11.
- 4 19. Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG and Brown NJ. High-
5 Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery. *Jama*. 2016;315.
- 6 20. Baran Ç, Durdu S, Dalva K, Zaim Ç, Dogan A, Ocakoglu G, Gürman G, Arslan Ö and Akar AR.
7 Effects of Preoperative Short Term Use of Atorvastatin on Endothelial Progenitor Cells after Coronary
8 Surgery: A Randomized, Controlled Trial. *Stem Cell Reviews and Reports*. 2012;8:963-971.
- 9 21. Carrascal Y, Arnold RJ, De la Fuente L, Revilla A, Sevilla T, Arce N, Laguna G, Pareja P and Blanco
10 M. Efficacy of atorvastatin in prevention of atrial fibrillation after heart valve surgery in the PROFACE
11 trial (PROphylaxis of postoperative atrial Fibrillation After Cardiac surgEry). *Journal of Arrhythmia*.
12 2016;32:191-197.
- 13 22. Castano M, Gonzalez-Santos JM, Lopez J, Garcia B, Centeno JE, Aparicio B, Bueno MJ, Diez R,
14 Sagredo V, Rodriguez JM and Garcia-Criado FJ. Effect of preoperative oral pravastatin reload in
15 systemic inflammatory response and myocardial damage after coronary artery bypass grafting. A pilot
16 double-blind placebo-controlled study. *J Cardiovasc Surg (Torino)*. 2015;56:617-29.
- 17 23. Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agrò F, Carassiti M and Covino E.
18 Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. *Critical Care*
19 *Medicine*. 2006;34:660-667.
- 20 24. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative
21 thrombocytosis and thrombotic complications following CABG1. *European Journal of Cardio-Thoracic*
22 *Surgery*. 1999;15:394-400.
- 23 25. Mannacio VA, Iorio D, De Amicis V, Di Lello F and Musumeci F. Effect of rosuvastatin
24 pretreatment on myocardial damage after coronary surgery: A randomized trial. *The Journal of*
25 *Thoracic and Cardiovascular Surgery*. 2008;136:1541-1548.
- 26 26. Park JH, Shim J-K, Song J-W, Soh S and Kwak Y-L. Effect of atorvastatin on the incidence of
27 acute kidney injury following valvular heart surgery: a randomized, placebo-controlled trial. *Intensive*
28 *Care Medicine*. 2016;42:1398-1407.
- 29 27. Prowle JR, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Haase M, Haase-Fielitz A, Bagshaw
30 SM, Devarajan P and Bellomo R. Pilot double-blind, randomized controlled trial of short-term
31 atorvastatin for prevention of acute kidney injury after cardiac surgery. *Nephrology*. 2012;17:215-224.
- 32 28. Spadaccio C, Pollari F, Casacalenda A, Alfano G, Genovese J, Covino E and Chello M.
33 Atorvastatin Increases the Number of Endothelial Progenitor Cells After Cardiac Surgery: A
34 Randomized Control Study. *Journal of Cardiovascular Pharmacology*. 2010;55:30-38.
- 35 29. Ferguson TW, Komenda P and Tangri N. Cystatin C as a biomarker for estimating glomerular
36 filtration rate. *Current Opinion in Nephrology and Hypertension*. 2015;24:295-300.
- 37 30. Helmersson-Karlqvist J, Lipcsey M, Ärnlov J, Bell M, Ravn B, Dardashti A and Larsson A. Cystatin
38 C predicts long term mortality better than creatinine in a nationwide study of intensive care patients.
39 *Scientific Reports*. 2021;11.
- 40 31. Nair V, Robinson-Cohen C, Smith MR, Bellovich KA, Bhat ZY, Bobadilla M, Brosius F, de Boer
41 IH, Essioux L, Formentini I, Gadegbeku CA, Gipson D, Hawkins J, Himmelfarb J, Kestenbaum B, Kretzler
42 M, Magnone MC, Perumal K, Steigerwalt S, Ju W and Bansal N. Growth Differentiation Factor-15 and
43 Risk of CKD Progression. *Journal of the American Society of Nephrology*. 2017;28:2233-2240.
- 44 32. Su H, Lei C-T and Zhang C. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An
45 Update. *Frontiers in Immunology*. 2017;8.
- 46 33. Reinhart K, Karzai W and Meisner M. Procalcitonin as a marker of the systemic inflammatory
47 response to infection. *Intensive Care Medicine*. 2014;26:1193-1200.
- 48 34. Zakiyanov O, Kalousová M, Zima T and Tesař V. Placental Growth Factor in Patients with
49 Decreased Renal Function. *Renal Failure*. 2011;33:291-297.
- 50 35. Sabbiseti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A, Ito K, Sharma S,
51 Ramadesikan S, Lee M, Briskin R, De Jager PL, Ngo TT, Radlinski M, Dear JW, Park KB, Betensky R,

- 1 Krolewski AS and Bonventre JV. Blood Kidney Injury Molecule-1 Is a Biomarker of Acute and Chronic
2 Kidney Injury and Predicts Progression to ESRD in Type I Diabetes. *Journal of the American Society of*
3 *Nephrology*. 2014;25:2177-2186.
- 4 36. Schmidt IM, Srivastava A, Sabbisetti V, McMahon GM, He J, Chen J, Kusek JW, Taliercio J,
5 Ricardo AC, Hsu C-y, Kimmel PL, Liu KD, Mifflin TE, Nelson RG, Vasan RS, Xie D, Zhang X, Palsson R,
6 Stillman IE, Rennke HG, Feldman HI, Bonventre JV and Waikar SS. Plasma Kidney Injury Molecule 1 in
7 CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies. *American Journal of Kidney*
8 *Diseases*. 2022;79:231-243.e1.
- 9 37. Singer E, Markó L, Paragas N, Barasch J, Dragun D, Müller DN, Budde K and Schmidt-Ott KM.
10 Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. *Acta*
11 *Physiologica*. 2013;207:663-672.
- 12 38. McMahon GM, Zeng X and Waikar SS. A Risk Prediction Score for Kidney Failure or Mortality
13 in Rhabdomyolysis. *JAMA internal medicine*. 2013;173.
- 14 39. Section 2: AKI Definition. *Kidney International Supplements*. 2012;2:19-36.
- 15 40. Zhang Z, Lu B, Sheng X and Jin N. Cystatin C in Prediction of Acute Kidney Injury: A Systemic
16 Review and Meta-analysis. *American Journal of Kidney Diseases*. 2011;58:356-365.
- 17 41. Rubin D. *Multiple imputation for non-response in surveys*. New York: John Wiley; 1987.
- 18 42. Gumbert SD, Kork F, Jackson ML, Vanga N, Ghebremichael SJ, Wang CY and Eltzschig HK.
19 Perioperative Acute Kidney Injury. *Anesthesiology*. 2020;132:180-204.
- 20 43. Mangano CM. Renal Dysfunction after Myocardial Revascularization: Risk Factors, Adverse
21 Outcomes, and Hospital Resource Utilization. *Annals of Internal Medicine*. 1998;128.
- 22 44. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman
23 VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting
24 HH, Uretsky BF and Wijeyesundera DN. 2014 ACC/AHA Guideline on Perioperative Cardiovascular
25 Evaluation and Management of Patients Undergoing Noncardiac Surgery. *Circulation*. 2014;130.
- 26 45. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I,
27 Geisler T, Hinterbuchner L, Ibanez B, Lenarczyk R, Mansmann UR, McGreavy P, Mueller C, Muneretto
28 C, Niessner A, Potpara TS, Ristić A, Sade LE, Schirmer H, Schüpke S, Sillesen H, Skulstad H, Torracca L,
29 Tutarel O, Van Der Meer P, Wojakowski W, Zacharowski K, Knuuti J, Kristensen SD, Aboyans V, Ahrens
30 I, Antoniou S, Asteggiano R, Atar D, Baumbach A, Baumgartner H, Böhm M, Borger MA, Bueno H,
31 Čelutkienė J, Chieffo A, Cikes M, Darius H, Delgado V, Devereaux PJ, Duncker D, Falk V, Fauchier L,
32 Habib G, Hasdai D, Huber K, lung B, Jaarsma T, Konradi A, Koskinas KC, Kotecha D, Landmesser U, Lewis
33 BS, Linhart A, Løchen ML, Maeng M, Manzo-Silberman S, Mindham R, Neubeck L, Nielsen JC, Petersen
34 SE, Prescott E, Rakisheva A, Saraste A, Sibbing D, Siller-Matula JM, Sitges M, Stankovic I, Storey RF,
35 Berg Jt, Thielmann M, Touyz RM, Bouzid MA, Sisakian H, Metzler B, Shumavets V, Pasquet A, Smajic E,
36 Milanova M, Skorić B, Karakyriou M, Skalicka H, Maeng M, Elhamid BA, Ruusalepp A, Valtola K, Cohen
37 A, Chukhrkidze A, Ott I, Kafkas N, Járαι Z, Hrafnkelsdóttir TJ, Campbell P, Eisen A, Urbinati S,
38 Aidargaliyeva N, Batalli A, Lunegova O, Erglis A, Saade G, Macas A, Banu C, Felice T, Grosu A,
39 Vukmirovic M, Soufiani A, Dubois E, Pejkov H, Aune E, Bartuś S, Santos, Mário, Badila E, Irtyuga O,
40 Bertelli L, Beleslin B, Dúbrava M, Fras Z, Ferreira JL, Held C, Meyer P, Bsata W, Halima AB, Biteker M,
41 Archbold A, Sokolov M, Zakirov N, Knuuti J, Kristensen SD, Aboyans V, Ahrens I, Antoniou S, Asteggiano
42 R, Atar D, Baumbach A, Baumgartner H, Böhm M, Borger MA, Bueno H, Čelutkienė J, Chieffo A, Cikes
43 M, Darius H, Delgado V, Devereaux PJ, Duncker D, Falk V, Fauchier L, Habib G, Hasdai D, Huber K, lung
44 B, Jaarsma T, Konradi A, Koskinas KC, Kotecha D, Landmesser U, Lewis BS, Linhart A, Løchen ML, Maeng
45 M, Manzo-Silberman S, Mindham R, Neubeck L, Nielsen JC, Petersen SE, Prescott E, Rakisheva A,
46 Saraste A, Sibbing D, Siller-Matula J, Sitges M, Stankovic I, Storey RF, ten Berg J, Thielmann M and
47 Touyz RM. 2022 ESC Guidelines on cardiovascular assessment and management of patients
48 undergoing non-cardiac surgery. *European heart journal*. 2022.
- 49 46. Ward NC, Watts GF and Eckel RH. Statin Toxicity. *Circulation Research*. 2019;124:328-350.
- 50 47. Bosch X, Poch E and Grau JM. Rhabdomyolysis and Acute Kidney Injury. *New England Journal*
51 *of Medicine*. 2009;361:62-72.

- 1 48. Benedetto U, Angeloni E, Luciani R, Refice S, Stefanelli M, Comito C, Roscitano A and Sinatra
2 R. Acute kidney injury after coronary artery bypass grafting: Does rhabdomyolysis play a role? *The*
3 *Journal of Thoracic and Cardiovascular Surgery*. 2010;140:464-470.
- 4 49. Singh N, Lee JZ, Huang JJ, Low SW, Howe C, Pandit A, Suryanarayana P and Lee KS. Benefit of
5 statin pretreatment in prevention of contrast-induced nephropathy in different adult patient
6 population: systematic review and meta-analysis. *Open Heart*. 2014;1.
- 7 50. Putzu A, de Carvalho e Silva CMPD, de Almeida JP, Belletti A, Cassina T, Landoni G and Hajjar
8 LA. Perioperative statin therapy in cardiac and non-cardiac surgery: a systematic review and meta-
9 analysis of randomized controlled trials. *Annals of Intensive Care*. 2018;8.

1 **Table 1: Characteristics of the patients at baseline.**

Characteristic	Rosuvastatin (n=960)	Placebo (n=962)
Age		
Mean – years	59.3±9.4	59.5±9.5
≤60 years	516 (53.8%)	504 (52.4%)
>60 years	444 (46.3%)	458 (47.6%)
Female sex		
	194 (20.2%)	205 (21.3%)
Body-mass index, kg/m ²	25.7±3.2	25.7±3.1
CKD-EPI estimated GFR (ml/min/1.73m ²)‡	90±15	90±15
Current smoker	229 (23.9%)	245 (25.5%)
Medical history		
Hypertension	621 (64.7%)	614 (63.8%)
Myocardial infarction	282 (29.4%)	274 (28.5%)
Stroke/transient ischaemic attacks	115 (12.0%)	119 (12.4%)
Peripheral arterial disease	23 (2.4%)	19 (2.0%)
Heart failure	46 (4.8%)	37 (3.8%)
Chronic obstructive pulmonary disease	5 (0.5%)	14 (1.5%)
Diabetes mellitus	310 (32.3%)	291 (30.2%)
Chronic kidney disease	10 (1.0%)	8 (0.8%)
Contrast agents (last 2 weeks)	383 (39.9%)	379 (39.4%)
Current/recent medication§		
Beta-blocker	813 (84.7%)	804 (83.6%)
NSAID or glucocorticoid	16 (1.7%)	7 (0.7%)
Insulin	140 (14.6%)	158 (16.4%)
Antiplatelet or anticoagulant	792 (82.5%)	779 (81.0%)
Calcium-channel blocker	445 (46.4%)	424 (44.1%)
ACE inhibitor or ARB	385 (40.1%)	384 (39.9%)
Nitrate	798 (83.1%)	800 (83.2%)
Diuretic agent	197 (20.5%)	213 (22.1%)
Statin	321 (33.4%)	332 (34.5%)
Scheduled surgery		
On-pump procedure	508 (52.9%)	515 (53.5%)
Off-pump procedure	422 (44.0%)	429 (44.6%)
CABG	832 (86.7%)	838 (87.1%)
Aortic-valve replacement	117 (12.2%)	119 (12.4%)

Plus-minus values are means ±SD.

‡ The glomerular filtration rate (GFR) was estimated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

§ Recent medication included antiplatelet agents, which are routinely stopped 5 to 7 days before surgery.

ACE denotes angiotensin converting enzyme, ARB angiotensin-receptor blocker, CABG coronary-artery bypass grafting, and NSAID nonsteroidal anti-inflammatory drug.

Table reproduced with permission from Zheng et al.¹⁷

2

3

1 **Table 2: Age- and fully-adjusted relevance of each baseline measure to the odds of**
2 **creatinine-defined AKI among 1852 participants who had either CABG or AVR (or both)**

Variable	SD/N (%)	Age-adjusted		Fully-adjusted	
		OR (95% CI)	X ²	OR (95% CI)	X ²
Age, per 10 years	9.3	1.31 (1.16, 1.49)	19.0	1.25 (1.09, 1.43)	10.7
Female sex	381 (20.6%)	0.68 (0.51, 0.91)	7.1		
Current smoker	462 (24.9%)	0.80 (0.61, 1.04)	2.8		
Per 1 SD higher BMI	3.2	1.09 (0.98, 1.22)	2.5		
Medical history					
CKD	16 (0.9%)	2.98 (1.10, 8.06)	4.4		
Heart failure	79 (4.3%)	1.46 (0.88, 2.41)	2.1		
Diabetes mellitus	583 (31.5%)	1.17 (0.93, 1.48)	1.8		
Hypertension	1200 (64.8%)	1.17 (0.92, 1.48)	1.6		
COPD	16 (0.9%)	1.84 (0.66, 5.10)	1.3		
PAD	37 (2.0%)	0.85 (0.38, 1.87)	0.2		
Myocardial infarction	537 (29.0%)	1.02 (0.80, 1.29)	0.0		
Stroke	224 (12.1%)	0.99 (0.71, 1.38)	0.0		
Recent/current medication					
Beta-blocker	1573 (84.9%)	0.66 (0.49, 0.89)	7.3		
Insulin	288 (15.6%)	1.45 (1.09, 1.92)	6.3	1.41 (1.05, 1.91)	5.0
Contrast agent (2 wks)	742 (40.1%)	0.78 (0.62, 0.97)	4.9	0.70 (0.55, 0.89)	8.8
ACE or ARB	737 (39.8%)	1.20 (0.96, 1.50)	2.6		
Nitrate	1555 (84.0%)	0.85 (0.63, 1.14)	1.1		
Diuretic agent	380 (20.5%)	0.86 (0.65, 1.14)	1.1		
Statins	628 (33.9%)	0.91 (0.72, 1.15)	0.6		
APT or ACOAG	1529 (82.6%)	0.89 (0.67, 1.20)	0.6		
Calcium-channel blocker	846 (45.7%)	1.06 (0.85, 1.32)	0.3		
Biomarkers at baseline, per 1 SD					
Higher log Creatinine	0.2	1.42 (1.27, 1.58)	40.2	1.34 (1.20, 1.50)	26.3
Higher log KIM-1	0.5	1.42 (1.27, 1.59)	39.3	1.31 (1.17, 1.47)	20.9
Lower eGFR	15.1	1.43 (1.27, 1.61)	33.1		
Higher log GDF15	0.5	1.29 (1.15, 1.45)	18.1		
Higher log NT-pro BNP	1.3	1.24 (1.11, 1.39)	13.8		
Higher log Procalcitonin	0.5	1.12 (1.01, 1.24)	4.5		
Higher log NGAL	0.3	1.09 (0.98, 1.22)	2.5		
Higher log sCD40L	0.9	0.93 (0.83, 1.03)	1.9		
Higher log Troponin	1.2	1.06 (0.95, 1.18)	1.2		
Higher log Interleukin-6	0.6	1.02 (0.92, 1.14)	0.2		
Higher log PLGF	0.3	0.99 (0.88, 1.10)	0.1		
Higher LDL cholesterol	0.7	0.99 (0.89, 1.11)	0.0		
Surgery received					
Surgery type			14.8		12.6
CABG only	1614 (87.1%)	1.00		1.00	
AVR only	185 (10.0%)	1.33 (0.92, 1.94)		1.47 (1.00, 2.17)	
Both	53 (2.9%)	2.90 (1.66, 5.07)		2.60 (1.45, 4.67)	
On-pump vs. off-pump	1034 (55.8%)	1.30 (1.04, 1.63)	5.3		
Rosuvastatin vs. placebo		1.40 (1.13, 1.75)	9.1	1.43 (1.14, 1.80)	9.8
C-statistic (95% CI)				0.66 (0.63, 0.69)	

- 1 CI, confidence interval; log, Natural logarithm; OR, Odds ratio; SD, standard deviation.
- 2 For regression models, any missing values were replaced with the mean value for continuous outcomes or the modal value for binary outcomes.
- 3

1 **Table 3: Age- and fully-adjusted relevance of each baseline measure to the odds of cystatin**
2 **C-defined AKI among 1852 participants who had either CABG or AVR (or both)**

Variable	SD/N (%)	Age-adjusted		Fully-adjusted	
		OR (95% CI)	X ²	OR (95% CI)	X ²
Age, per 10 years	9.3	1.27 (1.04, 1.55)	5.6	1.06 (0.85, 1.32)	0.2
Female sex	381 (20.6%)	1.35 (0.91, 2.02)	2.1		
Current smoker	462 (24.9%)	0.71 (0.45, 1.13)	2.2		
Per 1 SD higher BMI	3.2	0.86 (0.72, 1.03)	2.7		
Medical history					
CKD	16 (0.9%)	1.57 (0.35, 7.06)	0.3		
Heart failure	79 (4.3%)	2.98 (1.62, 5.48)	10.1		
Diabetes mellitus	583 (31.5%)	1.55 (1.09, 2.22)	5.7		
Hypertension	1200 (64.8%)	1.35 (0.91, 1.99)	2.3		
COPD	16 (0.9%)	1.64 (0.37, 7.32)	0.4		
PAD	37 (2.0%)	0.32 (0.04, 2.32)	1.9		
Myocardial infarction	537 (29.0%)	1.06 (0.72, 1.55)	0.1		
Stroke	224 (12.1%)	1.21 (0.73, 1.99)	0.5		
Recent/current medication					
Beta-blocker	1573 (84.9%)	0.57 (0.36, 0.88)	6.0		
Insulin	288 (15.6%)	1.89 (1.25, 2.85)	8.4	1.70 (1.09, 2.65)	5.1
Contrast agent (2 wks)	742 (40.1%)	1.13 (0.80, 1.61)	0.5		
ACE or ARB	737 (39.8%)	1.72 (1.21, 2.44)	9.1	1.91 (1.32, 2.77)	11.6
Nitrate	1555 (84.0%)	0.75 (0.47, 1.18)	1.5		
Diuretic agent	380 (20.5%)	0.93 (0.60, 1.45)	0.1		
Statins	628 (33.9%)	0.77 (0.52, 1.13)	1.9		
APT or ACOAG	1529 (82.6%)	0.72 (0.46, 1.12)	2.0		
Calcium-channel blocker	846 (45.7%)	0.98 (0.69, 1.40)	0.0		
Biomarkers at baseline, per 1 SD					
Higher log Creatinine	0.2	1.10 (0.93, 1.30)	1.2		
Higher log KIM-1	0.5	1.58 (1.34, 1.86)	28.4	1.37 (1.15, 1.63)	12.4
Lower eGFR	15.1	1.27 (1.06, 1.53)	6.3		
Higher log GDF15	0.5	1.22 (1.02, 1.46)	4.4		
Higher log NT-pro BNP	1.3	1.71 (1.43, 2.05)	34.3	1.54 (1.26, 1.87)	19.0
Higher log Procalcitonin	0.5	1.18 (1.03, 1.36)	4.8		
Higher log NGAL	0.3	0.91 (0.76, 1.09)	1.1		
Higher log sCD40L	0.9	0.86 (0.73, 1.00)	3.4		
Higher log Troponin	1.2	1.23 (1.04, 1.45)	5.8		
Higher log Interleukin-6	0.6	1.00 (0.84, 1.20)	0.0		
Higher log PLGF	0.3	0.89 (0.74, 1.07)	1.6		
Higher LDL cholesterol	0.7	1.20 (1.02, 1.41)	4.7		
Surgery received					
Surgery type			26.5		20.6
CABG only	1614 (87.1%)	1.00		1.00	
AVR only	185 (10.0%)	1.51 (0.85, 2.71)		1.61 (0.87, 3.00)	
Both	53 (2.9%)	6.11 (3.28, 11.38)		5.25 (2.68, 10.30)	
On-pump vs. off-pump	1034 (55.8%)	1.90 (1.30, 2.76)	11.7		
Rosuvastatin vs. placebo		1.95 (1.35, 2.80)	13.4	2.01 (1.38, 2.93)	13.7
C-statistic (95% CI)				0.73 (0.68, 0.78)	

- 1 CI, confidence interval; log, Natural logarithm; OR, Odds ratio; SD, standard deviation.
- 2 For regression models, any missing values were replaced with the mean value for continuous outcomes or the modal value for binary outcomes.
- 3

1 **Table 4: Fully-adjusted relevance of selected baseline measures to the odds of creatinine-**
 2 **defined and cystatin C-defined AKI among 1852 participants who had either CABG or AVR**
 3 **(or both)**

Variable	SD/N (%)	Creatinine-defined AKI		Cystatin C-defined AKI	
		OR (95% CI)	X ²	OR (95% CI)	X ²
Age, per 10 years	9.3	1.25 (1.09, 1.43)	10.7		
Insulin	288 (15.6%)	1.41 (1.05, 1.91)	5.0	1.70 (1.09, 2.65)	5.1
Contrast agent (2 wks)	742 (40.1%)	0.70 (0.55, 0.89)	8.8		
ACE or ARB	737 (39.8%)			1.91 (1.32, 2.77)	11.6
Higher log Creatinine	0.2	1.34 (1.20, 1.50)	26.3		
Higher log KIM-1	0.5	1.31 (1.17, 1.47)	20.9	1.37 (1.15, 1.63)	12.4
Higher log NT-pro BNP	1.3			1.54 (1.26, 1.87)	19.0
Surgery type			12.6		20.6
CABG only	1614 (87.1%)	1.00		1.00	
AVR only	185 (10.0%)	1.47 (1.00, 2.17)		1.61 (0.87, 3.00)	
Both	53 (2.9%)	2.60 (1.45, 4.67)		5.25 (2.68, 10.30)	
Rosuvastatin vs. placebo		1.43 (1.14, 1.80)	9.8	2.01 (1.38, 2.93)	13.7

4
 5 CI, confidence interval; log, Natural logarithm; OR, Odds ratio; SD, standard deviation.
 6 For regression models, any missing values were replaced with the mean value for continuous outcomes or the
 7 modal value for binary outcomes. Variables were selected for inclusion in this Table if they were statistically
 8 significant in either the fully-adjusted model for creatinine-defined AKI or in the fully-adjusted model for cystatin
 9 C-defined AKI; variables that were statistically significant in both models are highlighted in bold.

Figure 1: Effect of allocation to rosuvastatin on creatinine-defined and cystatin C-defined AKI, and on post-operative creatinine and cystatin C levels




Figure 1: Effect of allocation to rosuvastatin on creatinine-defined and cystatin C-defined AKI, and on post-operative creatinine and cystatin C levels. The upper panel shows bar graphs indicating proportion of AKI stages 1-3 at 48 hours post-operatively in the rosuvastatin and placebo groups, defined by creatinine (**panel A**) and cystatin C (**panel B**). Participants missing cystatin C or creatinine were assumed not to have AKI unless they had undergone renal replacement therapy. The lower panel shows bar graphs indicating levels of creatinine (**panel C**) and cystatin C (**panel D**) at baseline and at 48 hours post-operatively in the rosuvastatin and placebo groups. Bars show geometric means with approximate \pm SE. P values were derived from analysis of covariance with adjustment for the baseline value with any missing data imputed with the use of multiple imputation.

Figure 2: Effect of allocation to rosuvastatin on postoperative creatinine-defined AKI, overall and according to subgroups




Figure 2: Effect of allocation to rosuvastatin on postoperative creatinine-defined AKI, overall and according to subgroups. Forest plot indicating the effect of rosuvastatin versus placebo on post-operative AKI according to pre-specified subgroups. 142 participants with missing baseline and/or 48hr creatinine levels and who did not undergo renal replacement therapy were assumed to not have had the event. The denominator for coronary-artery bypass grafting (CABG) includes only patients who had CABG without aortic-valve replacement, and the denominator for aortic-valve replacement includes only those who had aortic-valve replacement without CABG. Participants with a missing value for a particular subgroup are not shown (but do contribute to the overall diamond). 101 participants were missing baseline Troponin. 48 participants were scheduled for surgery but did not undergo surgery; these individuals are excluded from the relevant subgroups. Risk groups were defined using the predicted values from a logistic regression that included age and five variables found to be associated with AKI risk in 1,852 participants who underwent CABG or AVR surgery in an age-adjusted multivariate model that included treatment allocation: baseline creatinine, baseline KIM-1, procedure (CABG only/AVR only/both), insulin use, and contrast agent use. Abbreviations: OR, odds ratio; CI, confidence interval.

Figure 3: Effect of allocation to rosuvastatin on postoperative concentrations of biomarkers of inflammation and renal injury




Figure 3: Effect of allocation to rosuvastatin on postoperative concentrations of biomarkers of inflammation and renal injury. Bar graphs indicating levels of growth differentiation factor 15 (GDF-15; **panel A**), interleukin-6 (IL-6; **panel B**), procalcitonin (**panel C**), placental growth factor (PLGF; **panel D**), kidney injury molecule-1 (KIM-1; **panel E**), and neutrophil gelatinase-associated lipocalin (NGAL; **panel F**) at baseline and post-operatively in the rosuvastatin and placebo groups. P values were derived from analysis of covariance with adjustment for the baseline value with any missing data imputed with the use of multiple imputation. Bars show geometric means with approximate \pm SE.